Light Therapy on Sleep Quality in Dialysis Patients

Hemodialysis Clinical Trial

— LUMIDIAL  

Official title:

Randomized Open-label Trial Evaluating Light Therapy on Sleep Quality in Dialysis Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04089397
• Other study ID #: 17-11-LUMIDIAL
• Secondary ID: 2018-A02276-49
• Status: Completed
• Phase: N/A
• Start date: October 1, 2019
• Est. completion date: May 11, 2020

Study information

• Verified date: November 2019
• Source: Centre Hospitalier Annecy Genevois
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sleep disorders are common in dialysis patients. At present, the management of insomnia in patients with chronic renal failure is not significantly different from that of the general population, which focuses on the management of co-factors, sleep hygiene, and cognitive-behavioral therapy. Light therapy is a paramedical practice that involves exposing a patient to a light intensity greater than 5000 Lux (usually 10,000 Lux) for 30 minutes in the morning between 7:00 and 8:30. Its impact is partly mediated by an improvement in the nycthemeral cycle of melatonin. Light therapy may improve sleep disorders and anxious-depressive elements as suggested in the literature. This technique has not yet been evaluated in dialysis patients, whereas easy to set up.

Description:

Sleep disorders are common in dialysis patients. Indeed, several studies have reported that the prevalence of these disorders is higher than that of the general population. At present, the management of insomnia in patients with chronic renal failure is not significantly different from that of the general population, which focuses on the management of co-factors, sleep hygiene, and cognitive-behavioral therapy. Light therapy is a paramedical practice that involves exposing a patient to a light intensity greater than 5000 Lux (usually 10,000 Lux) for 30 minutes in the morning between 7:00 and 8:30. Its impact is partly mediated by an improvement in the nycthemeral cycle of melatonin. Light therapy has been studied in several pathologies. In the context of renal insufficiency, only one randomized study was conducted in renal transplant patients: out of 30 patients, the effect of light therapy regained an 11-minute increase in sleep latency, an earlier awakening of 24 minutes, and a gain in the DASS-21 depression score of 1.7 points while there was no improvement in his three parameters in the control group. Interest in light therapy has also been evaluated in seasonal and non-seasonal depression. In a meta-analysis of 458 patients, light therapy adjuvant use was as effective as the addition of a second molecule. Light therapy may improve sleep disorders and anxious-depressive elements as suggested in the literature. This technique has not yet been evaluated in dialysis patients, whereas easy to set up. We therefore wish to set up a clinical study to determine whether a light therapy technique in the morning during dialysis or at home improves the quality of sleep of chronic hemodialysis patients. The secondary objectives will be to specify the improved sleep parameters, to evaluate the impact on the anxious-depressive score, the arterial hypertension, and the nutritional state, and the residual effect of light therapy. The aim of this trial is to determine whether a light therapy technique in the morning during dialysis or at home improves the quality of sleep of chronic hemodialysis patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: May 11, 2020
• Est. primary completion date: May 11, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient in conventional hemodialysis or hemodiafiltration for at least 3 months
• Patient requiring a dialysis session three times a week in the investigational site
• Patient benefiting from a social security scheme
• Patient informed and having given his free and informed consent to participate in the study

Exclusion Criteria:

• Patient with binocular blindness and / or age-related macular degeneration
• Eye fatigue
• Patient who has undergone a recent eye surgery (less than 3 months) or for whom such an operation is planned in the next 20 weeks
• Patient taking medications known to be responsible for photosensitivity
• Pregnant or lactating woman
• Patient under guardianship or curatorship
• Patient unable to give free and informed consent Exclusion during the study - premature stop
• Wishes of the patient or the physician
• Appearance of unexplained visual disturbances
• Kidney transplant

Related Conditions & MeSH terms

• Chronic Renal Failure
• Hemodialysis
• Kidney Failure, Chronic
• Light Therapy
• Parasomnias
• Sleep Disorder
• Sleep Wake Disorders

Intervention

Device:
• Light Therapy
Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis

Locations

Country	Name	City	State
France	CH Annecy Genevois	Pringy

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Annecy Genevois

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Impact of light therapy on the quality of sleep of dialysis patients	The Pittsburgh Sleep Quality Index (PSQI) questionnaire is a self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.; The primary endpoint is the measured difference in PSQI score between baseline and 5 weeks post-exposure to light therapy between the two arms of the study (no light therapy versus active light therapy).	5 weeks
Secondary	Pathological sleep disorders defined by PSQI score > 5	Percentage of patients with a PSQI score > 5 measured in both arms at baseline and after 5 weeks	5 weeks
Secondary	Analysis of each component of the PSQI score	There are 7 components in the PSQI score (sleep duration, sleep disturbance, sleep latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality, and sleep medication use). Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction.; Difference of the medians obtained on each component of the PSQI score in both arms at baseline and after 5 weeks	5 weeks
Secondary	Anxious-depressive state of the patients	The French Depression Anxiety Stress Scales (DASS 21) is a 21-item self-rated questionnaire designed to measure the emotional states of depression, anxiety and stress over the past week. The scale to which each item belongs is indicated by the letter D (Depression), A (Anxiety) and S (Stress). For each scale, scores are summed with the higher scores corresponding to the most severe status.; Total score difference obtained from the questionnaire French Depression Anxiety Stress Scales (DASS 21) in both arms at baseline and after 5 weeks	5 weeks
Secondary	Impact of light therapy on nutritional intake of patients	The normalized protein catabolic rate is a formula commonly used to assess dietary protein intake in dialysis patients, as a means towards determining nutritional adequacy.; Absolute difference in Normalized Protein Catabolic Rate value in both arms at baseline, after 5 weeks and 10 weeks	10 weeks
Secondary	Systolic Blood Pressure values	Absolute difference in systolic blood pressure in both arms at baseline, after 5 weeks and 10 weeks	10 weeks
Secondary	Diastolic Blood Pressure values	Absolute difference in diastolic blood pressure in both arms at baseline, after 5 weeks and 10 weeks	10 weeks
Secondary	Side effects of light therapy	Number and frequency of side effects	5 weeks
Secondary	Impact of home care on the effectiveness of the primary endpoint	The Pittsburgh Sleep Quality Index (PSQI) questionnaire is a self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.; Difference in the average PSQI score between the two subgroups: home care versus during dialysis light therapy	5 weeks
Secondary	Evaluation of the residual duration of the effect of light therapy on sleep disorder	The Pittsburgh Sleep Quality Index (PSQI) questionnaire is a self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality.; Average difference in PSQI score at the end of the procedure and 5 weeks later.	5 weeks
Secondary	Evaluation of the residual duration of the effect of light therapy on anxious-depressive state of the patients	The French Depression Anxiety Stress Scales (DASS 21) is a 21-item self-rated questionnaire designed to measure the emotional states of depression, anxiety and stress over the past week. The scale to which each item belongs is indicated by the letter D (Depression), A (Anxiety) and S (Stress). For each scale, scores are summed with the higher scores corresponding to the most severe status.; Average difference in DASS 21 score, at the end of the procedure and 5 weeks later.	5 weeks